Chronic Hepatitis C: Treatment Options and Definition - Internal Medicine

More Info

---

Chronic Hepatitis C is a long-term infection caused by the Hepatitis C virus (HCV), which primarily affects the liver. After initial infection, approximately 80-90% of individuals will develop chronic hepatitis C. Over time, this condition can lead to serious complications, including liver cirrhosis and hepatocellular carcinoma (liver cancer). The progression to cirrhosis occurs in about 20% of those with chronic hepatitis C after 20 years, and patients with cirrhosis face an annual risk of developing liver cancer of 3-6%.

Definition of Chronic Hepatitis C:
Chronic Hepatitis C is defined as the presence of HCV in the blood for more than six months. The virus can cause inflammation of the liver, leading to symptoms such as fatigue, jaundice (yellowing of the skin and eyes), and abdominal discomfort. However, many individuals may remain asymptomatic for years, making regular screening and monitoring essential for early detection and management.

Treatment Options for Chronic Hepatitis C:
The treatment landscape for chronic hepatitis C has evolved significantly, particularly with the advent of direct-acting antiviral (DAA) therapies. Historically, treatment involved the use of interferon (either standard or pegylated) combined with ribavirin. Interferon is an immune-modulating agent that can help the body fight the virus, while ribavirin is an antiviral medication that inhibits viral replication.

1. Interferon-based Therapy:
- Standard Interferon: Administered subcutaneously or intramuscularly, typically three times a week for six months to a year.

- Pegylated Interferon: A longer-acting form that is injected once a week, often combined with ribavirin.

2. Ribavirin: This medication is taken orally and is dosed based on the patient's weight. It is used in combination with interferon to enhance the antiviral effect.

However, it is important to note that these treatments are not effective for all patients. Approximately 60% of patients may not achieve a sustained virologic response (SVR), which is considered a cure. Factors such as the viral genotype (with genotype 1 being the most challenging) and high pretreatment viral load can affect treatment outcomes.

3. Direct-Acting Antivirals (DAAs): The introduction of DAAs has revolutionized the treatment of chronic hepatitis C. These medications target specific steps in the HCV life cycle and have shown high efficacy rates, often exceeding 95%. DAAs are typically administered for 8 to 12 weeks and have fewer side effects compared to interferon-based therapies. Common DAAs include:
- Sofosbuvir
- Ledipasvir
- Velpatasvir
- Glecaprevir/Pibrentasvir
DAAs have become the standard of care due to their high cure rates, shorter treatment duration, and improved tolerability.

Monitoring and Follow-Up:
Monitoring liver function tests (such as AST and ALT) and HCV RNA levels is crucial during and after treatment. While a decrease in liver enzymes indicates improved liver health, the primary measure of treatment success is achieving an undetectable HCV RNA level, which signifies that the virus has been cleared from the body.

Conclusion:
Chronic Hepatitis C is a serious condition that requires careful management and treatment. With the availability of effective antiviral therapies, many patients can achieve a cure and prevent the progression of liver disease. It is essential for individuals diagnosed with chronic hepatitis C to work closely with their healthcare providers to determine the most appropriate treatment plan based on their specific circumstances and health status. Regular follow-up and monitoring are vital to ensure the best possible outcomes.